Annexon, Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). We show 19 historical shares outstanding datapoints in our coverage of ANNX's shares outstanding history.
Understanding the changing numbers of ANNX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ANNX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ANNX by allowing them to research ANNX shares outstanding history
as well as any other stock in our coverage universe. |
Free ANNX Email Alerts:
Video: Shares Outstanding Importance
